Cann Group Past Performance
Past criteria checks 0/6
Cann Group's earnings have been declining at an average annual rate of -35.3%, while the Pharmaceuticals industry saw earnings growing at 22.5% annually. Revenues have been growing at an average rate of 53.9% per year.
Key information
-35.3%
Earnings growth rate
-12.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 22.5% |
| Revenue growth rate | 53.9% |
| Return on equity | -49.8% |
| Net Margin | -257.2% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Cann Group (ASX:CAN) Is Making Moderate Use Of Debt
May 18
Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now
Nov 03Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation
Feb 23What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Nov 25
One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be
Nov 25Earnings and Revenue History
Quality Earnings: CAN is currently unprofitable.
Growing Profit Margin: CAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 35.3% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.8%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-49.83%), as it is currently unprofitable.